Company intelligence / Profile preview

Vivace Design

San Mateo, California, United Statesvivacedesignbuild.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 3

Overview

VT3989, the company's lead compound, has been evaluated in more than 150 patients in an ongoing Phase 1 clinical study and has demonstrated promising efficacy and excellent safety profile. The company is planning to advance to a registrational Phase 3 clinical trial in mesothelioma.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

cretostimogene

Phase 3

Indications: Non-Muscle Invasive Bladder Cancer (NMIBC), Muscle Invasive Bladder Cancer (MIBC)

Beyond the preview

Go deeper on Vivace Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivace Design.

Explore the full profile